Skip to main content

FDA accepts Mylan's application for MS generic


PITTSBURGH The Food and Drug Administration has accepted a generic drug maker’s approval application for a version of a multiple sclerosis drug.

Mylan announced Monday the FDA’s acceptance of its application for glatiramer acetate injection in the 20 mg-per-milliliter strength. Mylan has an agreement with NATCO Pharma, whereby Mylan receives exclusive distribution rights for pre-filled syringes of the drug in the United States, Canada, Europe, Australia, New Zealand and Japan.

The drug is a generic version of Teva’s Copaxone, which had global sales of $2.26 billion in 2007, according to Teva financial reports. According to the FDA’s Orange Book database, Teva’s patent on Copaxone, which the company considers its leading innovative product, expires in 2014.

This ad will auto-close in 10 seconds